-
[31] G.K. Mcevoy (Ed.): AHFS drug information, American society of hospital pharmacists Inc., Bethesda, 1992, pp. 1759–1763.
-
[32] J.E. Low: “Method of preventing ulcer formation caused by non steroidal anti-inflammatory drugs employing tetrazol-benzothiophene carboxamide compounds”, Chem. Abstr., Vol. 123, (1995), 102781f.
-
[33] C.S. Lai and T.M. Wang: “Protected forms of a conjugate combination of non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase 2 (COX-2) inhibitors and their therapeutic use”, Chem. Abstr., Vol. 136, (2002), 15235f.
-
[34] S.A. Cooper: “Analgesic and anti-inflammatory compositions containing COX-2 inhibitors”, Chem. Abstr., Vol. 136, (2002), 42872t.
-
[35] P.C. Isakson, G.D. Anderson and S.A. Gregory: “Treatment of inflammation and inflammation related disorders with a combination of COX-2 inhibitors and a 5-lipoxygenase inhibitor”, Chem. Abstr., Vol. 133, (2000), 321880n.
-
RELATION NAME
-
[37] T. Niho, I. Yamamoto, H. Mochizuki, I. Kimura, A. Imai and T. Nakase: “Pyrazine and quinoxaline derivatives and their use as antiulcer agents”, Chem. Abstr., Vol. 124, (1996), 202307v.
-
[38] M. Fujitake, N. Mikami, H. Kasukawa, Y. Suwabe and A. Ota: “Preparation of pyrazine derivatives as blood platelet aggregation inhibitors and anti-inflammatory agents”, Chem. Abstr., Vol. 115, (1991), 71654v.
-
[39] T. Kaneko, R. Clark, N. Ohi, F. Ozaki, T. Kawahara, A. Kamada, K. Okano, H. Yokohama, K. Muramoto, T. Arai, M. Ohkuro, O. Takenaka and J. Sonoda: “Preparation of pyrazinobenzothiazine derivatives and analogs for the treatment of inflammation and autoimmune disease”, Chem. Abstr., Vol. 128, (1998), 204878p.
-
[40] K. Abe, F. Tafusa, J. Namikawa and Y. Manabe: “Preparation of heterocyclylaminophenols as inflammation inhibitors”, Chem. Abstr., Vol. 113, (1990), 231408g.